Drugs / AIDSVAX B/E
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01931358 | Sep 2013 → Dec 2021 | HIV infectious disease | U.S. Army Medical Research and Development Command | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AIDSVAX B/E | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01931358 ↗ |
| Modality | Vaccine | “The RV144 phase 3 vaccine trial in Thailand demonstrated that ALVAC-HIV (vCP1521) and AIDSVAX B/E administration over 6 months resulted in a 31% efficacy in preventing HIV acquisition.” PMID 32035516 ↗ Feb 2020 |